Payment overview · 2025
General Payments
$745.37
48 reported records · 14 companies
Healthcare provider profile · identity verified
Christopher Duvall Sims, MD
Allopathic & Osteopathic Physicians|Family Medicine · STANFORD, KY · NPI 1386687457
Verified facts
What the public records show
CMS Open Payments records show Christopher Duvall Sims, MD received $745.37 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Nurtec Odt, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.84 | 20.4% | 15 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $106.21 | 14.2% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $72.44 | 9.7% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.68 | 7.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.59 | 7.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.66 | 7.2% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $53.25 | 7.1% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $49.03 | 6.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.70 | 5.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.64 | 4.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.19 | 3.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.61 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.46 | 1.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.07 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $745.37 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $106.21 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $85.96 | 10 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $72.44 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.61 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $65.88 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.68 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.59 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.66 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $53.25 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $49.03 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $37.70 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.64 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.19 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 33 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 385 | 108 |
| Lisinopril | Lisinopril | 372 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 345 | 87 |
| Omeprazole | Omeprazole | 305 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 57 |
| Metformin Hcl | Metformin Hcl | 233 | 55 |
| Gabapentin | Gabapentin | 190 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 41 |
| Losartan Potassium | Losartan Potassium | 152 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 140 | 30 |
| Furosemide | Furosemide | 138 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 32 |
| Montelukast Sodium | Montelukast Sodium | 121 | 31 |
| Simvastatin | Simvastatin | 120 | 34 |
| Potassium Chloride | Potassium Chloride | 113 | 29 |
| Trazodone Hcl | Trazodone Hcl | 108 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 27 |
| Clonazepam | Clonazepam | 101 | 12 |
| Ibuprofen | Ibuprofen | 100 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 98 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 91 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 17 |
| Tramadol Hcl | Tramadol Hcl | 78 | 15 |
| Atenolol | Atenolol | 73 | 16 |
| Sertraline Hcl | Sertraline Hcl | 70 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 18 |
| Prednisone | Prednisone | 69 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 57 | 13 |
| Novolog Flexpen | Insulin Aspart | 57 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 13 |
| Metformin Hcl Er | Metformin Hcl | 55 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 17 |
| Carvedilol | Carvedilol | 52 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 12 |
| Clonidine Hcl | Clonidine Hcl | 50 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 15 |
| Alprazolam | Alprazolam | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 12 |
| Ozempic | Semaglutide | 40 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 14 |
| Allopurinol | Allopurinol | 35 | 11 |
| Azithromycin | Azithromycin | 35 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Eliquis | Apixaban | 33 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Valsartan | Valsartan | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $745.37 · 48 records | ABBVIE INC. | Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FANAPT, MOUNJARO, NURTEC ODT, Ohtuvayre, QULIPTA, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Veozah, YUPELRI, ZEPBOUND, ZURZUVAE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error